Hearts & Minds Blog

Cost-Effective Innovation

Tim Mayleben

President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with… more

What’s Your “Why”?

Tim Mayleben

President and Chief Executive Officer

This past weekend Esperion participated, for the 15th year, in the American Heart Association’s (AHA) annual Heart Walk to raise… more

Posted In: Tim Mayleben

Reflections One Year Post-IPO

Tim Mayleben

President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million… more

Posted In: Company News

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density… more

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than… more